Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NHLBI TOPMed: The Vanderbilt Genetic Basis of Atrial Fibrillation

ABSTRACT: NHLBI TOPMed: The Vanderbilt Genetic Basis of Atrial Fibrillation

PROVIDER: PRJNA302084 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The Vanderbilt Atrial Fibrillation Ablation Registry

Project description:NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The Vanderbilt Atrial Fibrillation Ablation Registry

| PRJNA297607 | ENA

NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The Vanderbilt University BioVU Atrial Fibrillation Genetics Study

Project description:NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The Vanderbilt University BioVU Atrial Fibrillation Genetics Study

| PRJNA476028 | ENA

NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The Vanderbilt University BioVU Atrial Fibrillation Genetics Study

Project description:NHLBI TOPMed - Centers for Common Disease Genomics (CCDG): The Vanderbilt University BioVU Atrial Fibrillation Genetics Study

| PRJNA476027 | ENA

Atrial Fibrillation After Surgery for Colorectal Cancer

Project description:This study will report the incidence of atrial fibrillation after elective colorectal cancer resection in the over 65 age group. This will be used to validate a risk model for the development of post-operative atrial fibrillation. Eligible patients will undergo electrocardiogram based screening for atrial fibrillation, as well as brain natriuretic peptide tests prior to surgery. They will undergo 24 hour holter monitor prior to surgery, and at 30 and 90 days following surgery. The primary outcome will be occurrence of atrial fibrillation within 90 days of surgery. Secondary outcomes include quality of life change, use of hospital services for atrial fibrillation, and complications of atrial fibrillation. This will be used to validate the pre-existing model for prediction of atrial fibrillation.

| 2312263 | ecrin-mdr-crc

NHLBI TOPMed: Early-onset Atrial Fibrillation in the Estonian Biobank

Project description:NHLBI TOPMed: Early-onset Atrial Fibrillation in the Estonian Biobank

| PRJNA472129 | ENA

NHLBI TOPMed: Early-onset Atrial Fibrillation in the Estonian Biobank

Project description:NHLBI TOPMed: Early-onset Atrial Fibrillation in the Estonian Biobank

| PRJNA472128 | ENA

Atrial Fibrillation Patient's Urine miRNA Microarray

Project description:Analysis for early diagnosis of atrial fibrillation by finding changes in miRNA in the urine of patients with atrial fibrillation

2021-12-16 | GSE190898 | GEO

NHLBI TOPMed: The Cleveland Clinic Atrial Fibrillation Study of the CV/Arrhythmia Biobank

Project description:NHLBI TOPMed: The Cleveland Clinic Atrial Fibrillation Study of the CV/Arrhythmia Biobank

| PRJNA338828 | ENA

NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women

Project description:NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women

| PRJNA305781 | ENA

Regional transcriptomics of a human left atrium and implications for atrial fibrillation

Project description:Regional differential expression of atrial fibrillation risk genes in the left atrium and pulmonary veins is not well studied, but may yield insights into atrial fibrillation pathogenesis. We tested the hypothesis that there is significant regional differential expression in left atrium structures. RNAseq was performed in 25 regions within the pulmonary veins (n=12), left atrial body (n=10), and left atrial appendage (n=3) from a 75 year old male with hypertension and atrial fibrillation who died of a stroke. These data show that genes involved in atrial fibrillation pathogenesis have substantial regional expression heterogeneity, particularly when comparing the left atrial body, pulmonary veins and left atrial appendage.

2020-11-14 | GSE161450 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data